Moderna and Tabuk Pharmaceuticals Partner to Commercialize Moderna’s COVID-19 Vaccine in Saudi Arabia
June 11 2021 - 8:30AM
Business Wire
Agreement also includes distribution of
Moderna’s updated variant booster candidates
Moderna, Inc. (Nasdaq: MRNA), a
biotechnology company pioneering messenger RNA (mRNA) therapeutics
and vaccines, and Tabuk Pharmaceutical Manufacturing Company (a
fully owned subsidiary of Astra Industrial Group), a leading Saudi
pharmaceuticals company, today announced an agreement to
commercialize the Moderna COVID-19 Vaccine and future
variant-specific booster candidates in Saudi Arabia.
Under the terms of this agreement, Tabuk Pharmaceuticals will
hold the marketing authorization for the Moderna COVID-19 vaccine
in Saudi Arabia. Beyond the Moderna COVID-19 Vaccine and Moderna’s
updated variant booster candidates, the agreement also gives Tabuk
the possibility to discuss opportunities to distribute other
Moderna mRNA products if authorized in the future.
“We appreciate the collaboration of Tabuk Pharmaceuticals in
this new partnership in Saudi Arabia,” said Stéphane Bancel, Chief
Executive Officer of Moderna. “It is thanks to partnerships such as
these that we are able to expand access to our vaccine globally,
and we hope it will support the availability of our COVID-19
vaccine for the benefit of the people of Saudi Arabia.”
“We welcome the opportunity to work with Tabuk Pharmaceuticals
to bring the Moderna COVID-19 and potentially other Moderna mRNA
products to Saudi Arabia in the future,” said Corinne Le Goff,
Pharm.D., M.B.A., Chief Commercial Officer of Moderna. “Together
with our partners, we remain committed to delivering our vaccine to
more populations around the world. We are pleased to have secured a
new agreement to supply our COVID-19 vaccine and our updated
variant booster vaccine candidate, if authorized, to Saudi Arabia
for 2021 and 2022.”
“As part of our role and mission in Tabuk to deliver unique
health solutions and preserve lives for the people of Saudi Arabia
and countries we operate in especially during the current pandemic,
our partnership with Moderna comes in as an evident choice to
further support our mission in line with Saudi vision 2030
regarding biotechnology in association with such a distinguished
& renowned company as Moderna,” said Mohammed Alhagbani Astra
Industrial Group President.
“We are proud and excited at Tabuk to be partnering with Moderna
to commercialize crucial vaccines to Saudi Arabia building on our
strategy to expand our specialty and innovative business and
reinforces our leading position in the region. Our aspiration is to
be the partner of choice to Moderna in the region and consider
further strategic collaboration including local manufacturing in
Saudi,” said Wisam Alkhatib Pharm.,M.B.A., Vice President of
Strategy and Business Development of Tabuk Pharmaceuticals.
About Moderna
In 10 years since its inception, Moderna has transformed from a
science research-stage company advancing programs in the field of
messenger RNA (mRNA), to an enterprise with a diverse clinical
portfolio of vaccines and therapeutics across six modalities, a
broad intellectual property portfolio in areas including mRNA and
lipid nanoparticle formulation, and an integrated manufacturing
plant that allows for both clinical and commercial production at
scale and at unprecedented speed. Moderna maintains alliances with
a broad range of domestic and overseas government and commercial
collaborators, which has allowed for the pursuit of both
groundbreaking science and rapid scaling of manufacturing. Most
recently, Moderna’s capabilities have come together to allow the
authorized use of one of the earliest and most-effective vaccines
against the COVID-19 pandemic.
Moderna’s mRNA platform builds on continuous advances in basic
and applied mRNA science, delivery technology and manufacturing,
and has allowed the development of therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases, cardiovascular
diseases and auto-immune diseases. Today, 24 development programs
are underway across these therapeutic areas, with 14 programs
having entered the clinic. Moderna has been named a top
biopharmaceutical employer by Science for the past six years. To
learn more, visit www.modernatx.com.
About Tabuk
Established in Saudi Arabia in 1994, Tabuk Pharmaceuticals is a
leading regional pharmaceutical in the Middle East and North Africa
(MENA). Tabuk Pharmaceuticals develops, manufactures, markets and
distributes oral and injectable pharmaceutical products. The
company also contract manufactures high-quality pharmaceutical
products for third party multinational pharmaceutical companies and
has several established alliances that have helped launch some
innovative medications in the region. Tabuk Pharmaceuticals is a
major player in the industry in the Kingdom of Saudi Arabia and the
MENA region focusing and currently expanding into specialty therapy
areas and technologies. With more than 2,400 employees and four
state-of-the-art plants in Saudi Arabia and the region, serving
patients with unmet needs across 17 countries in MENA.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including regarding: the Company’s development of
a vaccine to protect against the SARS-CoV-2 virus (mRNA-1273, also
referred to as COVID-19 Vaccine Moderna and the Moderna COVID-19
Vaccine); and the Company’s agreement with Tabuk Pharmaceuticals to
distribute the Company’s products in Saudi Arabia. The
forward-looking statements in this press release are neither
promises nor guarantees, and you should not place undue reliance on
these forward-looking statements because they involve known and
unknown risks, uncertainties, and other factors, many of which are
beyond Moderna’s control and which could cause actual results to
differ materially from those expressed or implied by these
forward-looking statements. These risks, uncertainties, and other
factors include those other risks and uncertainties described under
the heading “Risk Factors” in Moderna’s most recent Annual Report
on Form 10-K filed with the U.S. Securities and Exchange Commission
(SEC) and in subsequent filings made by Moderna with the SEC, which
are available on the SEC’s website at www.sec.gov. Except as
required by law, Moderna disclaims any intention or responsibility
for updating or revising any forward-looking statements contained
in this press release in the event of new information, future
developments or otherwise. These forward-looking statements are
based on Moderna’s current expectations and speak only as of the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210611005274/en/
Media: Colleen Hussey Director, Corporate Communications
617-335-1374 Colleen.Hussey@modernatx.com
Investors: Lavina Talukdar Senior Vice President &
Head of Investor Relations 617-209-5834
Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Oct 2023 to Oct 2024